Actually Swami previously said that India will never be attractive to biological based scaffolds because of the infection risk in that environment (including the very high rates of antibiotic resistant bacterial infections). So there are simply NO competitors to BTM in the Indian market.
Ann: Chairman and CEO - AGM address to shareholders, page-30
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.35 |
Change
-0.040(1.67%) |
Mkt cap ! $1.623B | |||
| Open | High | Low | Value | Volume |
| $2.41 | $2.41 | $2.34 | $1.491M | 631.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3816 | $2.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.36 | 8900 | 2 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| PNV (ASX) Chart |